Tandem Diabetes Care Stock News

Tandem Diabetes Care (NASDAQ:TNDM) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close.The consensus EPS Estimate is $0.21 and the consensus

Riding The Stock Waves: Update On The Medical Devices Sector

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the global Artificial Pancreas Device System Market finds that, increasing prevalence of diabetes is expediting market growth. The market growth is attributed to increasing population across the globe as well as lack of precise effective substitute. Total global Artificial Pancreas Device System Market is estimated to reach USD 415.8 Million by 2028. The Market stood at a revenue of USD 95.6 Million in 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.1%. Furthermore, rising demand for automated systems for glycemic control, as well as increasing funding in Research and Development (R&D) is projected to augment growth of the global Artificial Pancreas Device System Market, states Vantage Market Research, in a report, titled " Artificial Pancreas Device System Market by Device (Threshold Suspended Device System, CTR System, CTT System), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

The U.S. Food and Drug Administration has cleared the first smartphone app to deliver insulin using the t:connect app from Tandem Diabetes Care, Inc.

Tandem Diabetes Care finally got clearance from the FDA for its insulin delivery app on iOS and Android. Learn more.

Nicole Wetsman / The Verge : Tandem Diabetes Care says one of its apps got FDA clearance to program insulin delivery for the company''s pump, the first such app to receive approval — t:slim X2 insulin pump users can use the app to program doses rather than the pump itself — The Food and Drug Administration cleared …

Photo Illustration by Matt Harbicht/Getty Images for Tandem Diabetes Care The Food and Drug Administration cleared a smartphone app from Tandem Diabetes Care to program insulin delivery for its t:slim X2 insulin pump, the company announced Wednesday . It’s the first phone app for both iOS and Android to able to deliver insulin, the company said in a statement. Previously, delivery had to be handled through the pump itself. With this update, pump users will be able to program or cancel bolus doses of insulin, which are taken at mealtimes and are crucial in keeping blood glucose levels under control. “Giving a meal bolus is now the most common reason a person interacts with their pump, and the ability to do so using a smartphone app offers a convenient and discrete solution,” John Sheridan, president and CEO of… Continue reading…

Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.

Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.

Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.

Investors are optimistic about Tandem Diabetes' (TNDM) t:slim X2 technology and greater use of Control-IQ technology.

These companies might struggle this year, but their prospects remain intact.